Ramy Masoud

Dr. Ramy Masoud

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAhmed Gamal
Ahmed Gamal
HBHany F. Badawy
Hany F. Badawy
ASAmira Said
Amira Said
MAMohammad Majed Al-Ahmad
Mohammad Majed Al-Ahmad
ARAlshaimaa Ibrahim Rabie
Alshaimaa Ibrahim Rabie
RIRabie M. Ibrahim
Rabie M. Ibrahim
Background: In men with progressive benign prostatic hyperplasia (BPH), acute urine retention (AUR) stands out as one of the most severe outcomes associated with aging. AUR is characterized by a sudden, painful inability to urinate. This research investigates the potential benefits of adding pyridostigmine to silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia. Methods: Patients aged 50 and above experiencing their first episode of AUR due to BPH, with a retention volume below 1000 milliliters, were enrolled in this study. A total of 140 patients were randomized into two groups: Group A received a daily dose of pyridostigmine bromide (60 mg tablet) alongside an 8 mg silodosin capsule, while Group B received a daily dose of silodosin (8 mg capsule) only. Trial registration number: NCT06319469 13 March 2024. Results: Among the 140 patients, 58 (82.9%) in Group A successfully underwent a trial without catheter (TWOC), compared to 47 (67.1%) in Group B. Group A exhibited significant improvements in international prostatic symptom score (IPSS) and uroflowmetry (UFR) at both 2 weeks and 3 months, with p-values of 0.001 and 0.003, respectively. Regarding postvoid residual volume (PVR), both groups were initially matched at baseline, showing significant continuous improvement at the second week and third month. Conclusions: The combination of pyridostigmine bromide (60 mg tablet) with silodosin proved to be more effective than silodosin alone in managing acute urinary retention caused by BPH. This was particularly true for patients who were suspected to have detrusor underactivity in addition to BPH.

10 April 2026 in Urology Research and Practice
Verified
Journal Article
Open access
PDF file
AGAhmed Gamal
Ahmed Gamal
OSOsama Sayed
Osama Sayed
RMRamy Masoud
Ramy Masoud
AMAmr Medhat Massoud
Amr Medhat Massoud
SHSherif Abdel Rahman Abdul Hay
Sherif Abdel Rahman Abdul Hay
HFHany Fathy
Hany Fathy
Objective: To compare the feasibility of bipolar transurethral enucleation (B-TUEP) and monopolar transurethral enucleation (M-TUEP) for the management of benign prostatic obstruction. Methods: This prospective randomized study involved 160 patients: 80 patients who were subjected to B-TUEP; and 80 patients who were subjected to M-TUEP. Patients were evaluated preoperatively and for 1 year postoperatively. Results: At the 12-month follow-up, no statistically significant intergroup differences were observed in operative time, resected tissue weight, International Prostate Symptom Score, or maximum urinary flow rate. Postoperative rates of re-catheterization for acute urinary retention, urinary incontinence, and urinary tract infections were also comparable between groups. However, the B-TUEP group exhibited significantly less intraoperative bleeding (P < .001). The M-TUEP group experienced significantly longer postoperative catheterization, and hospital stays (P < .001). Furthermore, the M-TUEP group demonstrated significantly lower mean intraoperative serum sodium levels (P < .001), with 1 patient experiencing TUR (Transurethral resection) syndrome. Conclusion: The findings indicate comparable efficacy between M-TUEP and B-TUEP for benign prostatic hyperplasia treatment, although B-TUEP demonstrates superior safety. Monopolar transurethral enucleation of the prostate remains a safe and effective alternative in the absence of bipolar technology. Cite this article as: Mohamed AG, Sayed O, Masoud RN, et al. Transurethral bipolar enucleation vs. transurethral monopolar enucleation of the prostate for the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. Urol Res Pract. 2026, 52, 0075 doi: 10.5152/ tud.2026.25075.